1 BTC
=
- USD
Windtree Therapeutics, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Windtree Therapeutics, Inc. Common Stock
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
Market Statistics
Trading Metrics
How to Buy WINT
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy WINT
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesEvofem Biosciences reported Q2 2025 financial results with 16% revenue growth to $4.8 million, driven by SOLOSEC acquisition and PHEXXI price adjustment. Despite operational improvements, the company experienced a net loss of $1.8 million and faces liquidity challenges ahead of a pending merger with Aditxt.
Windtree Therapeutics secures up to $520 million in funding through an equity line of credit and stock purchase agreement, with 99% of proceeds dedicated to acquiring BNB cryptocurrency as part of its innovative treasury strategy.
Windtree Therapeutics, a biotechnology company, announced the appointment of Leanne Kelly to its board of directors. Ms. Kelly has significant public company executive experience and will serve as an independent director and chair of the audit committee.
